.jetcityimage/iStock Editorial through Getty Images Morgan Stanley has opted for Eli Lilly (NYSE: LLY) as its top biopharma pick for 2025 and also rated an additional 9 labels in the room as over weight. The financial investment banking company stated in a keep in mind that it continues to believe “diabesity is set to come to be.